Search Results: 100% Pass Quiz High Pass-Rate Juniper - JN0-281 - Data Center, Associate (JNCIA-DC) New Braindumps Ebook 🐍 Open ➽ www.pdfvce.com 🢪 enter ➡ JN0-281 ️⬅️ and obtain a free download 🔮Valid Exam JN0-281 Book
Excerpt from the Press Release: SAN DIEGO–(BUSINESS WIRE)–Pipeline Therapeutics, a clinical-stage biopharmaceutical company pioneering precision neuroregeneration, today reported positive clinical data from its recently completed Phase 1 clinical trial evaluating the safety and tolerability of PIPE-307 in healthy volunteers. PIPE-307, the company’s lead program for myelin restoration, is an oral, highly selective antagonist of the…
Read More
Excerpt from the Press Release: PLEASANTON, Calif., Feb. 22, 2024 (GLOBE NEWSWIRE) — ProSomnus, Inc. (NASDAQ: OSA) (the “Company”), the leading non-CPAP Obstructive Sleep Apnea (OSA) therapy™, announced results of its pilot study for the Company’s Next Generation Remote Patient Monitoring (RPM) device for Obstructive Sleep Apnea (OSA). Data from the pilot study demonstrated that…
Read More
– Twist Bioscience to Offer Clinically Validated, Expert-Designed Exome Panel that Enriches Loci Relevant to Cancer, Rare and Inherited Diseases – Excerpt from the Press Release: SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced an…
Read More
Company Expects Phase 2 Data with Second Drug Candidate (CST-103) in Neurodegenerative Diseases in Third Quarter of 2022 Excerpt from the Press Release: SAN CARLOS, Calif.–(BUSINESS WIRE)–CuraSen Therapeutics, Inc., a clinical-stage company developing small molecule therapies to treat neurodegenerative disease, announced that it has begun dosing patients in a Phase 2a clinical trial with CST-2032,…
Read More
Primary endpoint data expected in Q1 2022 SAN FRANCISCO–(BUSINESS WIRE)–Better Therapeutics, Inc. (“Better Therapeutics”; NASDAQ: BTTX), a prescription digital therapeutics company developing cognitive behavioral therapy to address the root causes of cardiometabolic diseases, today announced the completion of patient enrollment in its potentially pivotal study to evaluate the safety and efficacy of BT-001 for the…
Read More
Excerpt from the Press Release: SAN FRANCISCO, CA / ACCESSWIRE / July 20, 2021 / Oncology Pharma Inc. (OTC PINK:ONPH) Oncology Pharma, Inc. (the “Company”) is laying out and taking necessary steps to move its licensed IP forward. From obtaining the necessary financing, in order to support studies, to obtaining the data utilizing mouse or rat…
Read More
Excerpt from the Press Release: NATICK, Mass.–(BUSINESS WIRE)–Naveris, Inc., a leader in molecular diagnostics for viral cancers, today announced the presentation of significant new data at the plenary session of the ASTRO 2022 Multidisciplinary Head and Neck Cancers Symposium supporting the clinical value of its flagship diagnostic test, NavDx®. In a real-world analysis of 1,076…
Read More
– Topline Data Expected First Quarter 2023 – Excerpt from the Press Release: DUBLIN, Ireland and FORT WASHINGTON, Pa., Aug. 11, 2022 (GLOBE NEWSWIRE) — Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, announced the completion of patient enrollment in its…
Read More
–Final data and potential for $25m milestone anticipated in H1 2023– Excerpt from the Press Release: SAN DIEGO, Feb. 24, 2022 /PRNewswire/ — Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the “Company” or “Regulus”), today announced the completion of enrollment in the Phase 2 HERA clinical study…
Read More
– GTB-3650 is a novel molecule based on camelid single-domain antibody technology with advantages that build upon the strong proof-of-concept data from the Company’s first-generation TriKE® program, GTB-3550 – GTB-3650 has shown significantly higher potency than GTB-3550 in preclinical models, as detailed in a recent peer reviewed publication¹ – Company now plans to accelerate its…
Read More